1a. Serological response to vaccination as measured by virus neutralization assay (VNA) titers and enzyme-linked immunosorbent assay (S-ELISA, ELISA Units/mL [EU/mL]), 28 days after Vaccination 2. 1b. Antibody geometric mean titers (GMTs) (VNA) and geometric mean concentrations (GMCs) (S-ELISA), 28 days after Vaccination 2. 2a. Serological response to vaccination as measured by VNA titers and ELISA (S-ELISA, EU/mL), 28 days after Vaccination 1. 2b. Antibody GMTs (VNA) and GMCs (S-ELISA), 28 days after Vaccination 1. 3a. Serological response to vaccination as measured by VNA titers and ELISA (S-ELISA, EU/mL), 28 days after Vaccination 2. 3b. Antibody GMTs (VNA) and GMCs (S-ELISA), 28 days after Vaccination 2. 4a. Solicited local and systemic adverse events (AEs) for 7 days after each vaccination. 4b. Unsolicited AEs for 28 days after each vaccination. 4c. Serious adverse events (SAEs) throughout the study (from first vaccination until end of the study).

1a. Serological response to vaccination as measured by virus neutralization assay (VNA) titers and enzyme-linked immunosorbent assay (S-ELISA, ELISA Units/mL [EU/mL]), 28 days after Vaccination 2. 1b. Antibody geometric mean titers (GMTs) (VNA) and geometric mean concentrations (GMCs) (S-ELISA), 28 days after Vaccination 2. 2a. Serological response to vaccination as measured by VNA titers and ELISA (S-ELISA, EU/mL), 28 days after Vaccination 1. 2b. Antibody GMTs (VNA) and GMCs (S-ELISA), 28 days after Vaccination 1. 3a. Serological response to vaccination as measured by VNA titers and ELISA (S-ELISA, EU/mL), 28 days after Vaccination 2. 3b. Antibody GMTs (VNA) and GMCs (S-ELISA), 28 days after Vaccination 2. 4a. Solicited local and systemic adverse events (AEs) for 7 days after each vaccination. 4b. Unsolicited AEs for 28 days after each vaccination. 4c. Serious adverse events (SAEs) throughout the study (from first vaccination until end of the study).

1a. Serological response to vaccination as measured by enzyme-linked immunosorbent assay (S-ELISA, ELISA Units/mL [EU/mL]), 28 days after Vaccination 2. 1b. Antibody geometric mean concentrations (GMCs) (S-ELISA), 28 days after Vaccination 2. 2a. Serological response to vaccination as measured by ELISA (S-ELISA, EU/mL), 28 days after Vaccination 1. 2b. Antibody GMCs (S-ELISA), 28 days after Vaccination 1. 3a. Serological response to vaccination as measured by ELISA (S-ELISA, EU/mL), 28 days after Vaccination 2. 3b. Antibody GMCs (S-ELISA), 28 days after Vaccination 2. 4a. Solicited local and systemic adverse events (AEs) for 7 days after each vaccination. 4b. Unsolicited AEs for 28 days after each vaccination. 4c. Serious adverse events (SAEs) throughout the study (from first vaccination until end of the study).

1a. Serological response to vaccination as measured by enzyme-linked immunosorbent assay (S-ELISA, ELISA Units/mL [EU/mL]), 28 days after Vaccination 2. 1b. Antibody geometric mean concentrations (GMCs) (S-ELISA), 28 days after Vaccination 2. 2a. Serological response to vaccination as measured by ELISA (S-ELISA, EU/mL), 28 days after Vaccination 1. 2b. Antibody GMCs (S-ELISA), 28 days after Vaccination 1. 3a. Serological response to vaccination as measured by ELISA (S-ELISA, EU/mL), 28 days after Vaccination 2. 3b. Antibody GMCs (S-ELISA), 28 days after Vaccination 2. 4a. Solicited local and systemic adverse events (AEs) for 7 days after each vaccination. 4b. Unsolicited AEs for 28 days after each vaccination. 4c. Serious adverse events (SAEs) throughout the study (from first vaccination until end of the study).

1a. Serological response to vaccination as measured by virus neutralization assay (VNA) titers and enzyme-linked immunosorbent assay (S-ELISA, ELISA Units/mL [EU/mL]), 28 days after Vaccination 2. 1b. Antibody geometric mean titers (GMTs) (VNA) and geometric mean concentrations (GMCs) (S-ELISA), 28 days after Vaccination 2. 2a. Serological response to vaccination as measured by VNA titers and ELISA (S-ELISA, EU/mL), 28 days after Vaccination 1. 2b. Antibody GMTs (VNA) and GMCs (S-ELISA), 28 days after Vaccination 1. 3a. Serological response to vaccination as measured by VNA titers and ELISA (S-ELISA, EU/mL), 28 days after Vaccination 2. 3b. Antibody GMTs (VNA) and GMCs (S-ELISA), 28 days after Vaccination 2. 4a. Solicited local and systemic adverse events (AEs) for 7 days after each vaccination. 4b. Unsolicited AEs for 28 days after each vaccination. 4c. Serious adverse events (SAEs) throughout the study (from first vaccination until end of the study).

1a. Serological response to vaccination as measured by virus neutralization assay (VNA) titers and enzyme-linked immunosorbent assay (S-ELISA, ELISA Units/mL [EU/mL]), 28 days after Vaccination 2. 1b. Antibody geometric mean titers (GMTs) (VNA) and geometric mean concentrations (GMCs) (S-ELISA), 28 days after Vaccination 2. 2a. Serological response to vaccination as measured by VNA titers and ELISA (S-ELISA, EU/mL), 28 days after Vaccination 1. 2b. Antibody GMTs (VNA) and GMCs (S-ELISA), 28 days after Vaccination 1. 3a. Serological response to vaccination as measured by VNA titers and ELISA (S-ELISA, EU/mL), 28 days after Vaccination 2. 3b. Antibody GMTs (VNA) and GMCs (S-ELISA), 28 days after Vaccination 2. 4a. Solicited local and systemic adverse events (AEs) for 7 days after each vaccination. 4b. Unsolicited AEs for 28 days after each vaccination. 4c. Serious adverse events (SAEs) throughout the study (from first vaccination until end of the study).